Stockscreener 앱 받기
0.832
13.33%
-0.128
전일 마감가:
$0.96
열려 있는:
$0.95
하루 거래량:
115.25K
Relative Volume:
1.14
시가총액:
$15.90M
수익:
$19.91M
순이익/손실:
$-127.11M
주가수익비율:
-0.0987
EPS:
-8.428
순현금흐름:
$-132.44M
1주 성능:
-14.23%
1개월 성능:
+45.94%
6개월 성능:
-77.27%
1년 성능:
-84.65%
1일 변동 폭
$0.825
$0.9544
1주일 범위
$0.825
$1.13
52주 변동 폭
$0.52
$8.95
Affimed N V Stock (AFMD) Company Profile
AFMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AFMD
Affimed N V
|
0.8321 | 15.90M | 19.91M | -127.11M | -132.44M | -8.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.86 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.15 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.66 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
272.65 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.85 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-12 | 개시 | H.C. Wainwright | Buy |
| 2022-10-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-10-21 | 개시 | Truist | Buy |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2018-08-28 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2016-08-12 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-05-19 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2015-12-10 | 개시 | Laidlaw | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-09-09 | 개시 | Jefferies | Hold |
| 2015-08-06 | 재확인 | Oppenheimer | Outperform |
| 2015-06-22 | 재확인 | Jefferies | Buy |
모두보기
Affimed N V 주식(AFMD)의 최신 뉴스
Affimed (NASDAQ:AFMD) Now Covered by StockNews.com - Defense World
Affimed Delays Filing of 2024 Yearly Report - TipRanks
Affimed Shows Higher Exposure of AFM24 is Associated with Signif - GuruFocus
Affimed Shows Higher Exposure of AFM24 is Associated with - GlobeNewswire
Affimed N.V. Reports Positive Findings on AFM24's Exposure-Outcome Analysis in Refractory Non-Small Cell Lung Cancer Patients - Nasdaq
Breakthrough: AFM24 Cancer Drug Achieves 33% Response Rate in Lung Cancer with New Dosing Strategy - Stock Titan
Affimed (NASDAQ:AFMD) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Affimed (NASDAQ:AFMD) Coverage Initiated at StockNews.com - Defense World
Affimed Announces Acceptance of Three Abstracts for Presentation - GuruFocus
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting | AFMD Stock News - GuruFocus
Affimed N.V. Announces Accepted Abstracts for Oral and Poster Presentations at ASCO 2025 Annual Meeting - Nasdaq
Affimed Announces Acceptance of Three Abstracts for - GlobeNewswire
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting - TradingView
Affimed faces Nasdaq delisting over share price rule By Investing.com - Investing.com Canada
Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode - NewsBreak: Local News & Alerts
Affimed Faces Nasdaq Delisting Risk Due to Share Price - TipRanks
Affimed faces Nasdaq delisting over share price rule - Investing.com Australia
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding - GuruFocus
Affimed (AFMD) Faces Nasdaq Delisting Risk Due to Low Share Price | AFMD Stock News - GuruFocus
Affimed (AFMD) Faces Nasdaq Delisting Risk Over Share Price - GuruFocus
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | AFMD Stock News - GuruFocus
Affimed N.V. Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Nasdaq
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire
Affimed Gets 180-Day Nasdaq Grace Period After Stock Falls Below $1, Extension Possible - Stock Titan
Affimed N.V. Receives EUR 2.4 Million Research Grant from German Government to Fund Trispecific Abs - marketscreener.com
Affimed (NASDAQ:AFMD) Now Covered by Analysts at StockNews.com - Defense World
Affimed (NASDAQ:AFMD) Receives $13.50 Average Target Price from Analysts - Defense World
Short Interest in Affimed (NASDAQ:AFMD) Declines By 14.9% - Defense World
Affimed Announces Acceptance of AFM24 Abstract on Dose - GlobeNewswire
Major Cancer Conference to Showcase New AFM24 Drug Optimization Results for Lung Cancer Treatment - Stock Titan
Affimed (AFMD) to Release Earnings on Thursday - Defense World
Affimed at Leerink’s Conference: Clinical and Strategic Insights - Investing.com
Affimed at Leerink’s Conference: Clinical and Strategic Insights By Investing.com - Investing.com UK
Affimed N.V. to Host Earnings Call - ACCESS Newswire
Can Affimed's CEO Presentation Signal New Oncology Breakthroughs? Conference Watch - StockTitan
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
Affimed Announces Proposed Public Offering Of Common Stock - Reuters
Short Interest in Affimed (NASDAQ:AFMD) Declines By 12.3% - Defense World
Affimed (NASDAQ:AFMD) Stock Passes Below Two Hundred Day Moving Average – Here’s Why - Defense World
Jane Street Group LLC Acquires New Position in Affimed (NASDAQ:AFMD) - Defense World
Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest - Defense World
HC Wainwright Issues Positive Forecast for Affimed Earnings - Defense World
Equities Analysts Offer Predictions for Affimed Q1 Earnings - Defense World
Affimed Shares Fall 32% on Clinical Update - GuruFocus.com
Affimed stock plunges 23% on AFM24 study update - MSN
Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha
Affimed N V (AFMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):